[go: up one dir, main page]

AR026275A1 - Compuestos farmaceuticos - Google Patents

Compuestos farmaceuticos

Info

Publication number
AR026275A1
AR026275A1 ARP000105680A ARP000105680A AR026275A1 AR 026275 A1 AR026275 A1 AR 026275A1 AR P000105680 A ARP000105680 A AR P000105680A AR P000105680 A ARP000105680 A AR P000105680A AR 026275 A1 AR026275 A1 AR 026275A1
Authority
AR
Argentina
Prior art keywords
substituted pyrimidine
derivatives
pharmaceutical compounds
pyrimidine derivatives
substituted
Prior art date
Application number
ARP000105680A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR026275A1 publication Critical patent/AR026275A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere al uso de ciertos derivados 4-sustituidos de la pirimidina como antagonistas de los receptores mGluR1, a nuevos derivados4-sustituidos de la pirimidina, a formulaciones farmacéuticas que comprenden derivados 4-sustituidos de la pirimidina, a un procedimiento para prepararderivados 4-sustituidos de la pirimidina y a intermedios utiles en la preparacion de derivados 4-sustituidos de la pirimidina.
ARP000105680A 1999-11-01 2000-10-27 Compuestos farmaceuticos AR026275A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16290099P 1999-11-01 1999-11-01

Publications (1)

Publication Number Publication Date
AR026275A1 true AR026275A1 (es) 2003-02-05

Family

ID=22587589

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105680A AR026275A1 (es) 1999-11-01 2000-10-27 Compuestos farmaceuticos

Country Status (7)

Country Link
EP (1) EP1230225A2 (es)
AR (1) AR026275A1 (es)
AU (1) AU1071301A (es)
CO (1) CO5261605A1 (es)
PE (1) PE20010854A1 (es)
SV (1) SV2002000205A (es)
WO (1) WO2001032632A2 (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429207B1 (en) 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
AU2003242252A1 (en) 2002-06-07 2003-12-22 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
US7423044B2 (en) 2002-09-05 2008-09-09 Wyeth Pyrimidine derivatives useful in the treatment of insulin resistance and hyperglycemia
TW200410975A (en) * 2002-09-26 2004-07-01 Nihon Nohyaku Co Ltd New pesticide and method for using it, new substituted thienopyrimidine derivative, its intermediate, and method for producing it
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
KR100772297B1 (ko) * 2002-11-22 2007-11-02 니뽄 다바코 산교 가부시키가이샤 융합 비시클릭 질소-함유 헤테로사이클
JP4666256B2 (ja) * 2002-12-10 2011-04-06 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
BRPI0409580A (pt) 2003-04-16 2006-04-18 Hoffmann La Roche compostos de quinazolina
BRPI0409405A (pt) 2003-04-16 2006-04-25 Hoffmann La Roche compostos 7-aza-quinazolina substituìdos
US7300932B2 (en) 2003-08-07 2007-11-27 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
WO2005016925A1 (en) * 2003-08-14 2005-02-24 Pfizer Limited Azaquinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US20070197510A1 (en) * 2004-03-10 2007-08-23 Kazuyuki Ohmoto Nitriles and medicinal compositions containing the same as the active ingredient
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
AR049300A1 (es) * 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
US7598259B2 (en) 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
ATE485300T1 (de) 2004-07-16 2010-11-15 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
US8283354B2 (en) 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
ZA200702375B (en) * 2004-09-02 2009-03-25 Vertex Pharma Quinazolines useful as modulators of ion channels
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
MX2007013595A (es) 2005-05-04 2008-01-24 Renovis Inc Compuestos heterociclicos fusionados y composiciones y usos de estos.
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
WO2007030582A2 (en) * 2005-09-09 2007-03-15 Bristol-Myers Squibb Company Acyclic ikur inhibitors
ES2562428T3 (es) 2005-12-15 2016-03-04 Rigel Pharmaceuticals, Inc. Inhibidores de cinasa y sus usos
HUP0501168A3 (en) * 2005-12-20 2007-10-29 Richter Gedeon Nyrt 2-(acyl, oxycarbonyl or aminocarbonyl)-3-phenyl-thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical composition containing them
US20090149495A1 (en) * 2005-12-20 2009-06-11 Katalin Nogradi Compounds
CA2630739A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. New compounds
HUP0501170A2 (en) * 2005-12-20 2007-09-28 Richter Gedeon Nyrt 2-heteroaryl-3-phenyl-thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical compositions containing them
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
ES2395386T3 (es) 2005-12-21 2013-02-12 Abbott Laboratories Compuestos antivirales
EP1979349B1 (en) 2005-12-21 2010-07-28 Abbott Laboratories Anti-viral compounds
NZ569817A (en) 2005-12-21 2011-10-28 Abbott Lab Anti-viral compounds
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
DE102006012251A1 (de) * 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JP2010510314A (ja) 2006-11-22 2010-04-02 シーサイド セラピューティクス，エルエルシー 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
WO2008095847A1 (de) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US20090209536A1 (en) * 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
ATE539075T1 (de) 2007-08-02 2012-01-15 Recordati Ireland Ltd Neue heterocyclische verbindungen als mglu5- antagonisten
TWI475995B (zh) 2007-09-14 2015-03-11 Janssen Pharmaceuticals Inc １’，３’－二取代－４－苯基－３，４，５，６－四氫－２ｈ，１’ｈ－〔１，４’〕聯吡啶基－２’－酮化物
ATE516272T1 (de) 2007-09-14 2011-07-15 Ortho Mcneil Janssen Pharm 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2009138781A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
WO2010059610A1 (en) * 2008-11-19 2010-05-27 Renovis, Inc. 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine compounds useful as faah modulators and uses thereof
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
CA2745295C (en) * 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
US20100317630A1 (en) 2009-02-04 2010-12-16 Recordati Ireland Limited Novel heterocyclic compounds as mglu5 antagonists
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2477981A1 (en) 2009-09-14 2012-07-25 Recordati Ireland Limited Heterocyclic mglu5 antagonists
WO2011106276A1 (en) * 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
MX2013000300A (es) 2010-07-09 2013-02-27 Recordati Ireland Ltd Nuevos compuestos espiroheterociclicos como antagonistas de mglu5.
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
US8551981B2 (en) 2010-10-08 2013-10-08 Abbvie Inc. Furo[3,2-d]pyrimidine compounds
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
WO2012062751A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
CN104203924B (zh) 2012-01-13 2019-06-11 艾森生物科学公司 杂环化合物及其作为抗癌药的用途
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
TWI499591B (zh) 2013-01-11 2015-09-11 Lilly Co Eli 雙環嘧啶化合物
TW201520219A (zh) * 2013-03-12 2015-06-01 Lilly Co Eli 咪唑並吡啶化合物
TW201500356A (zh) 2013-04-12 2015-01-01 Lilly Co Eli 二氫吡啶并嘧啶化合物
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
DK3019496T3 (da) 2013-07-11 2019-12-09 Acea Therapeutics Inc Pyrimidinderivater som kinaseinhibitorer
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PH12019500127B1 (en) 2014-01-21 2022-05-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
EP3424535A1 (en) 2014-01-21 2019-01-09 Janssen Pharmaceutica NV Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US9868744B2 (en) 2014-04-25 2018-01-16 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
WO2017004405A1 (en) * 2015-07-01 2017-01-05 Northwestern University Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity
JP6689297B2 (ja) 2015-07-23 2020-04-28 武田薬品工業株式会社 複素環化合物
MX2018004332A (es) 2015-10-09 2019-01-10 Acea Therapeutics Inc Sales farmaceuticas, formas fisicas y composiciones de inhibidores de pirrolopirimidina cinasa, y metodos para fabricar las mismas.
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
JP2020516682A (ja) 2017-04-07 2020-06-11 エイシア セラピューティクス， インコーポレイテッド ピロロピリミジンキナーゼの薬学的な塩、物理的形態および組成物、ならびにその作製方法
CN115605457B (zh) * 2021-04-26 2025-03-18 三菱瓦斯化学株式会社 化合物及其制造方法
WO2025188973A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of 22q11.2 deletion/duplication syndromes
US20250281498A1 (en) * 2024-03-06 2025-09-11 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1582407A (en) * 1977-06-07 1981-01-07 Worcester Controls Uk Ltd Annular seals
US5034393A (en) * 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
GB9823845D0 (en) * 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
DE19904710A1 (de) * 1999-02-05 2000-08-10 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-tetrahydrochinazoline, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
SE9903290D0 (sv) * 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds

Also Published As

Publication number Publication date
WO2001032632A3 (en) 2001-11-08
CO5261605A1 (es) 2003-03-31
SV2002000205A (es) 2002-06-07
PE20010854A1 (es) 2001-08-28
EP1230225A2 (en) 2002-08-14
WO2001032632A2 (en) 2001-05-10
AU1071301A (en) 2001-05-14

Similar Documents

Publication Publication Date Title
AR026275A1 (es) Compuestos farmaceuticos
DOP2001000195A (es) Derivados de purina
AR026052A1 (es) Derivados de purina
ECSP003531A (es) Derivados de purina
ECSP077259A (es) Derivados de pirimidina
ECSP003712A (es) Derivados de la purina
DOP2001000247A (es) Derivados de purina
SV2002000249A (es) Derivados de tiazolilamida ref, lea 34082-sv
ECSP066773A (es) Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la síntesis de los mismos
ECSP077233A (es) Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
ECSP099394A (es) Derivados de quinuclidinol como antogonistas de receptores muscarínicos
BRPI0918517B8 (pt) composto, composição farmacêutica, e, uso de um composto
UY27850A1 (es) Nuevos carbamatos de quinuclidina y composiciones farmacéuticas que los contienen
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
BR9809491A (pt) "derivados de ergolina e seu uso como antagonista de receptor de somatostatina"
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
HN2001000235A (es) Derivados puentes de piperazina
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
CR6398A (es) Antagonistas de 5ht1 para terapia antidepresiva
AR028743A1 (es) DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA
AR029617A1 (es) Procedimiento para preparar secretagogos de hormonas del crecimiento y polimorfo de los compuestos obtenidos
ECSP003748A (es) Compuestos farmaceuticos
HN2001000021A (es) Nuevos derivados de amidas heterociclicas
AR009322A1 (es) Nuevas aril-piridazinas

Legal Events

Date Code Title Description
FB Suspension of granting procedure